Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Citi
McKinsey
Baxter
Daiichi Sankyo
Federal Trade Commission
Moodys
Julphar
Novartis
Harvard Business School

Generated: October 20, 2017

DrugPatentWatch Database Preview

Fresenius Medcl Company Profile

« Back to Dashboard

What is the competitive landscape for FRESENIUS MEDCL, and what generic alternatives to FRESENIUS MEDCL drugs are available?

FRESENIUS MEDCL has nine approved drugs.

There are five US patents protecting FRESENIUS MEDCL drugs.

There are twenty-two patent family members on FRESENIUS MEDCL drugs in seventeen countries and thirty-seven supplementary protection certificates in ten countries.

Summary for Applicant: Fresenius Medcl

International Patents:22
US Patents:5
Tradenames:22
Ingredients:5
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Medcl
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL018379-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL018379-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL020171-001Aug 19, 1992ATRXNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
TABLET;ORAL019976-001Dec 10, 1990DISCNYesNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-001Apr 2, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
PHOSLO GELCAPS
calcium acetate
CAPSULE;ORAL021160-003Apr 2, 2001ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Fresenius Medcl
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER
calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL020171-003Aug 19, 1992ATRXNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL018379-008Jun 24, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
calcium chloride; dextrose; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL019395-003Mar 26, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Fresenius Medcl
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
calcium chloride; dextrose; sodium chloride; sodium lactate
SOLUTION;INTRAPERITONEAL019395-001Mar 26, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Fresenius Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Medcl
PHOSLO
calcium acetate
TABLET;ORAL019976-001Dec 10, 1990► Subscribe► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-001Apr 2, 2001► Subscribe► Subscribe
Fresenius Medcl
PHOSLO GELCAPS
calcium acetate
CAPSULE;ORAL021160-003Apr 2, 2001► Subscribe► Subscribe
Fresenius Medcl
PHOSLO
calcium acetate
CAPSULE;ORAL021160-002Apr 2, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FRESENIUS MEDCL drugs

Drugname Dosage Strength Tradename Submissiondate
calcium acetate
Oral Solution667 mg/5 mL
PHOSLYRA
12/5/2013
calcium acetate
CapsulesEQ 169 mg calcium
PHOSLO
5/31/2005

International Patent Family for Fresenius Medcl Drugs

Country Document Number Estimated Expiration
South Korea101553719► Subscribe
Israel196584► Subscribe
Japan5335674► Subscribe
Hong Kong1202815► Subscribe
European Patent Office2484352► Subscribe
Canada2658465► Subscribe
South Africa200900472► Subscribe
World Intellectual Property Organization (WIPO)2008011126► Subscribe
BrazilPI0714882► Subscribe
Russian Federation2463060► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Fresenius Medcl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/042United Kingdom► SubscribePRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020418
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
15/009Ireland► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
C0021France► SubscribePRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
/1997Austria► SubscribePRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
2008006Lithuania► SubscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
595Luxembourg► SubscribePRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Deloitte
Chinese Patent Office
Covington
Harvard Business School
Novartis
Accenture
Citi
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot